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 Abstract
 Backgrounds/Aims: The oxidative activity of ceruloplasmin (CP) in serum has been found to be 
lowered in patients with Alzheimer’s disease (AD). We investigated whether changes in CP were 
reflected by altered iron parameters in AD patients.  Methods: Iron parameters, and CP concen-
tration, activity and specific activity were determined in the serum of 41 AD patients and con-
trols.  Results: CP activity and specific activity were significantly lower in the AD patients. CP 
concentration and activity were negatively correlated with the ferritin concentration in both 
groups. CP concentration was positively correlated with age in the control group but not in the 
patients group.  Conclusion: The lowered CP activity in the serum of AD patients was not re-
flected by the iron parameters. As CP concentration only rises with age in the controls, this may 
indicate failing adaption to age-related alterations in iron metabolism in AD patients.
 Copyright © 2011 S. Karger AG, Basel
 Introduction
 Iron accumulates in the brain with normal aging  [1] . On the other hand, several authors 
have reported dysregulation of iron metabolism and oxidative stress due to redox-active iron 
in the brains of patients with Alzheimer’s disease (AD) and other neurodegenerative diseas-
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es  [2, 3] . Disturbances in iron metabolism may occur at several stages. Ceruloplasmin (CP) 
is crucial in the oxidation of Fe 2+  to Fe 3+ , which enables the binding of iron ions to transfer-
rin and thereby the transport of iron throughout the body. Increased lipid peroxidation and 
iron deposition have been found in the brain of patients with aceruloplasminemia  [4, 5] . 
These patients had raised serum ferritin, indicating iron overload, but low transferrin satu-
ration and mild anemia, which reflects the interaction between these three proteins. Fur-
thermore, they suffered from progressive neurological disorders, including extrapyramidal 
disorders and dementia. Transferrin is to a large extent responsible for the transfer of iron in 
the body. The genetic variant of transferrin, subtype C2, has been investigated as potential 
risk factor for AD but the results were controversial  [6, 7] .  A recent study reported an altered 
ratio between CP and transferrin in the serum of AD patients compared with healthy indi-
viduals, and this ratio was inversely correlated with Mini Mental State Examination (MMSE) 
scores  [8] . Ferritin is the main protein involved in iron storage. It accumulates in the brain 
as a result of normal aging, but differences in ferritin distribution in the brain between AD 
patients and controls have also been described  [2] .
 In a case-control study by Snaedal et al.  [9] in 1998, CP activity, but not CP concentra-
tion, was significantly lower in AD patients compared with controls. The aim of the present 
study was to verify the previously published results and investigate whether lowered CP ac-
tivity in the serum of AD patients reflects to a significant degree changes in the serum levels 
of iron, transferrin and ferritin, and transferrin saturation in these patients.
 Patients and Methods
 Patients
 Forty-one AD patients were included in the study. All patients had been examined at 
a psychogeriatric outpatient clinic and diagnosed with probable dementia of the Alzhei-
mer’s type according to the NINCS/ADRA criteria  [10] . Their mean MMSE score was 18 
(34 patients) and their mean age was 80 years ( table 1 ). All patients were living in their 
homes but attending day-care centers specialized in caring for people with dementia for 
social and medical support. Patients with a serious medical condition or taking drugs 
known to affect either liver or kidney function were excluded. Each patient had an age- and 
gender-matched control randomly selected from the Icelandic National Registry. All per-
sons in the control group were healthy and living independently in their homes. Exclusion 
criteria for the controls included a history of neurodegenerative disease, serious medical 
conditions or current drug treatment known to affect either liver or kidney function.   -
Glutamyl transpeptidase (GGT) was used as a marker for liver disease in the patients and 
the controls. Individuals exceeding twice the upper limits of GGT in healthy subjects were 
excluded from the study.
 Patients (males/females), n  41 (18/23) 
 Mean age (range), years  80 (65–88) 
 Mean MMSE score (range)  18 (6–27) 
 M MSE scores <24 indicate dementia; 34 patients were examined. 
 
 
 Table 1. C haracteristics of the 
study patients
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 Methods
 Fasting blood samples from patients and controls were obtained in the morning. The 
same blood sampling procedure was used for both groups, and the blood sampling units used 
were specially prepared for metal analysis (Sarstédt  ).
 The study was approved by the Icelandic National Bioethics Committee (04-121) and 
registered by the Data Protection Authority.
 GGT.  Serum GGT activity (U/l) was determined using a Vitros 950 (Ortho-Clinical Di-
agnostics, Rochester, N.Y., USA) at the Icelandic University Hospital Laboratories.
 CP Concentration.  Serum CP levels (mg/l) were determined using a rate nephelometry 
immunoassay (ICS-2; Beckman Instruments Inc., Fullerton, Calif., USA) at the Icelandic 
University Hospital Laboratories. The results are presented as milligrams per liter in  table 2 .
 Oxidative Activity of CP in the Serum. Oxidative activity of CP in the serum was deter-
mined at the Department of Pharmacology and Toxicology, University of Iceland, using the 
manual kinetic assay first described by Boyett  et al.  [11] in 1976 and later on by Transdottir 
et al.  [12] . The results are presented as units per milliliter in  table 2 .
 Serum Transferrin, Total Iron Binding Capacity and Transferrin Saturation.  Serum trans-
ferrin (mg/l) was determined at the Icelandic University Hospital Laboratories. It was mea-
sured with an immunoturbidimetric assay on a Hitachi 911 (Roche, Basel, Switzerland). To-
tal iron binding capacity was measured on a Vitros 5.1 from Ortho-Clinical Diagnostics 
(results not shown). Transferrin saturation (  mol/l) was calculated as follows: (100  ! serum 
iron)/total iron binding capacity. The results are presented in  table 2 .
 Serum Iron.  Serum iron was determined at the Icelandic University Hospital Laborato-
ries. It was also measured using a Vitros 5.1. The results are presented as micromoles per liter 
in  table 2 .
 Serum Ferritin.  Serum ferritin was determined at the Icelandic University Hospital Lab-
oratories. It was assessed using an electrochemiluminescence immunoassay (E-Modular) 
from Roche. The results are presented as micrograms per liter in  table 2 .
 Statistical Analysis
 As the results for the specific activity of CP and ferritin concentration in serum did not 
pass a normality test, the results shown in  table 2 were analyzed using the Mann-Whitney 
test. All the other determinations were also tested with Student’s t test (results not shown), 
but this did not change the significance of the results presented in  table 2 . For these calcula-
 Table 2. M ean CP, iron, ferritin and transferrin concentrations, CP oxidative activity, CP-specific oxida-
tive activity and transferrin saturation in AD patients and their gender- and age-matched controls 
 Determinations in serum  Patients  Controls  Pairs, n  p value 
 Serum CP oxidative activity, U/ml  119  136  41  0.0165 
 CP-specific oxidative activity, U/mg  568  611  40  0.0040 
 Concentrations 
 CP, mg/l  226  223  40  0.8501 
 Iron,   mol/l 15 18  41  0.0828 
 Ferritin,   g/l  114  141  40  0.2551 
 Transferrin, g/l 2.5 2.4  41  0.3011 
 Transferrin saturation,   mol/l 61 60  41  0.4808 
 T he number of pairs used for each analysis is indicated. The null hypothesis was rejected for p ≤ 0.05. 
The Mann-Whitney test was employed. 
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tions GraphPad Prism  was used. In this program, normality is calculated with both the 
Kolmogorov-Smirnov test and the newer D’Agostino-Pearson omnibus and Shapiro-Wilk 
tests. Linear regression was used to examine the correlation of age with ferritin, transferrin, 
CP concentration and CP activity. Furthermore, the correlation between CP concentration 
and CP activity was examined. Finally, the correlations between CP concentration and the 
concentration of ferritin and transferrin, respectively, were examined. Regression analyses 
were done with MedCalc  .
 Results
 The results of CP oxidative activity, CP-specific oxidative activity, concentrations of CP, 
iron, transferrin and ferritin, and transferrin saturation in AD patients and their gender- and 
age-matched controls are shown in  table 2 . CP concentration was positively correlated with 
age in the control group (p = 0.007), but it was negatively correlated with ferritin concentra-
tion in patients and controls (p = 0.004 and 0.006, respectively). CP activity was negatively 
correlated with the ferritin concentration in patients and controls (p = 0.042 and 0.001, re-
spectively).
 Discussion
 This study examined the concentration, activity and specific activity of CP in AD pa-
tients and healthy controls. No difference in CP concentration was found between the AD 
patients and the controls, but CP activity and specific activity (activity divided by mass) was 
significantly lower in the AD patients. In the study by Snaedal et al.  [9] , CP concentration 
was normal but CP activity was decreased in AD patients compared with controls, which is 
in agreement with our results and further supported by the results of Brewer et al.  [13] pub-
lished in 2010, who found no difference in CP concentration between AD patients and con-
trols, but circulating CP without oxidative activity was increased in AD patients. On the 
other hand, in a study by Squitti et al.  [14] , CP concentration was raised in the serum of AD 
patients. However, subsequently, the same authors found fragments of CP proteolysis in the 
serum of AD patients, possibly indicating impaired CP activity  [15] . In the plasma of patients 
with aberrant levels of amyloid   42 , tau and phosphorylated tau in the CSF, CP levels were 
decreased compared with AD patients with normal levels of these biomarkers in the CSF  [16] . 
Interestingly, CP has been found to be increased in the brain of AD patients, but only mod-
erately changed in neurons, and it was not related to the redox-active iron found in neurofi-
brillary tangles, indicating a failure in the response of neural induction of CP, resulting in 
the excessive accumulation of redox-active iron in the brain of AD patients  [17] . It is still not 
known whether there is a connection between these changes in the brain and the changes in 
AD blood found in the above studies.
 It seems that the patients in the present study ( table 1 ), the study by Brewer et al.  [13] and 
the patients with CSF-confirmed AD in the study by Kessler et al.  [16] are older and/or with 
more progressive AD than the patients in the study by Squitti et al.  [15] (2008). This may ex-
plain the discrepancy between the results of these studies and raises the question of whether 
early changes in CP are present in younger individuals who will later develop AD. It is pos-
sible that CP is increased in younger AD patients to compensate for increased oxidative load, 
but with progressing disease, the patients lose this ability to compensate, and CP activity thus 
declines. The fact that CP concentration was positively correlated with age in the controls 
but not in the AD patients may furthermore reflect a loss of compensation for oxidative stress 
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in progressing AD. This is in line with the results of Arnal et al.  [3] , who found plasma CP 
concentration to be lower in the latest stage of AD compared to earlier stages and that in 
healthy elderly controls  [18] . Another possibility is that a genetic defect in CP is a risk factor 
for AD, as has been suggested for patients with Parkinson’s disease. We calculated the spe-
cific activity of CP (activity/mass) and found it to be significantly lower in the blood of the 
AD patients than in the control group, most likely indicating a poorer quality of the CP pro-
tein in the AD patients. This is in line with results of studies on patients with Parkinson’s 
disease, in whom iron accumulation has been established in the substantia nigra along with 
genetic defects in CP  [3, 12, 19] . Taken together, these results may indicate that AD is a mul-
tifactorial disease with several risk factors, and that CP dysfunction resulting in oxidative 
stress may be one of the contributing factors, although it remains to be established whether 
it is caused by a genetic defect or acquired later in life.
 There was no significant difference in the iron and iron protein results between the AD 
patients and the controls ( table 2 ). This is in agreement with earlier work by Fischer et al. 
 [20] , who did not find a difference in the ferritin or transferrin concentration between AD 
patients and controls. However, our study showed a positive correlation between age and CP 
concentration in the controls, which was absent in the patients. Furthermore, CP concen-
tration and activity were negatively correlated with ferritin concentration in both the pa-
tients and the controls, reflecting an inverse relationship between CP and ferritin. This may 
indicate an increased iron load in the tissue of AD patients compared with the controls. Fer-
ritin is an intracellular iron storage protein, consisting of two subunits (a large and a small 
one) in different ratios in different tissues. The large subunit has ferroxidase activity, while 
the small subunit is associated with the mineralization of iron at the ferritin core  [21] . The 
ratio of heavy to light chains and the distribution of ferritin as well as the distribution of CP 
differ between AD patients and controls  [17, 22] . This raises the question of whether or not 
the ferroxidase activity of the larger subunits of ferritin and CP in the brain are related, and 
how disrupted interaction between the proteins may reflect the pathogenesis of AD.
 In the present study, we found no relationship between CP and transferrin, and no dif-
ference in transferrin concentration or saturation between the AD patients and the controls. 
Transferrin has not been studied in detail in the blood of AD patients. However, Squitti et al. 
 [8] found an altered CP/transferrin ratio between AD patients and controls, which was in-
versely correlated with the MMSE scores in AD patients. This is not in line with our results, 
and further studies are needed on the subject.
 In conclusion, there is evidence of disrupted regulation of iron and oxidative stress in 
the brain of AD patients. CP plays a central role in iron handling and is altered in both the 
brain and the blood of AD patients. In this study, CP activity and specific activity were sig-
nificantly lower in the AD patients compared with the controls. We found a negative corre-
lation between CP concentration/activity and ferritin concentration in the blood of both 
groups, indicating interplay between these proteins. However, as CP concentration fails to 
increase in AD patients with age, this may aggravate an age-related iron dysregulation in AD 
patients.
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